Fortified balance sheet, optimized operations, disciplined growth initiatives, and strategic hires set foundation for 2025 12,300 MW development pipeline with 2,800 MW under exclusivity as of December 31, 2024 Earnings Release HighlightsFull year 2024 revenue of $162.4 million, net income of $331.4 million, and Adjusted EBITDA of $555.7 million. Fourth quarter 2024 energy cost per megawatt-hour (“MWh”) of $31.63, a 30% decrease from the fourth quarter of 2023. Total energy capacity under management of 1,020 megawatts (“MW”) as of December 31, 2024. 12,300 MW development pipeline with 2,800 MW of capacity under exclusivity as of December 31, 2024. Strategic Bitcoin reserve of 10,171 Bitcoin with a market value of $949.5 million as of December 31, 2024.MIAMI, March 03, 2025 (GLOBE NEWSWIRE) — Hut 8 Corp. (Nasdaq | TSX: HUT) (“Hut...

For the three months and full-year ended December 31, 2024, from continuing operations:Revenues of $697.0 million for the fourth quarter, $2,696.4 million for the full year GAAP net loss of $(73.9) million for the fourth quarter, $(271.5) million for the full year Adjusted EBITDA of $56.0 million for the fourth quarter, $202.5 million for the full year Fourth-quarter book-to-bill ratio of 1.35xDURHAM, N.C., March 03, 2025 (GLOBE NEWSWIRE) — Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today reported financial results for the fourth quarter and full year ended December 31, 2024. “Our intense focus on our customers’ success and creating a better customer experience has resulted in the stronger demand that is reflected in this quarter’s book-to-bill,” said Tom Pike, chairman...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990) Phase 1b head-to-head study vs. DUPIXENT supported by positive APG990 interim Phase 1 results, which exceeded trial objectives and demonstrated potential for three- and six-month dosing in combination with APG777; APG279 readout expected in second half of 2026 $731.1 million cash, cash equivalents and marketable securities with runway into Q1 2028 SAN FRANCISCO and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets,...

Preliminary Statement of Results for the year ended 31 December 2024 Irish Continental Group (ICG), the leading Irish-based maritime transport group, reports its financial performance for the year ended 31 December 2024. HighlightsFinancial Summary          2024 2023 Change  Revenue   €603.8m €572.0m +5.6%  EBITDA   €133.5m €132.6m +0.7%  Operating profit   €69.1m €68.4m +1.0%  Basic earnings per share   36.3c 36.2c ...

EXOSENS DELIVERS VERY STRONG FULL-YEAR 2024 RESULTS, OVERPERFORMING ON ITS IPO GUIDANCE SUSTAINED GROWTH DYNAMIC ANTICIPATED FOR 2025-2026 FY 2024 HIGHLIGHTSStrong revenue growth of +35.0%, above IPO guidance, to €394.1m in 2024, reflecting dynamic like-for-like growth (+24.9%) and successful integration of bolt-on acquisitions Significant increase in profitability, with adjusted EBITDA of €118.5m in 2024 (+37.8%), representing a best-in-class margin of 30.1% (vs. 29.5% in 2023), above IPO guidance and above top range of estimated landing given in January 2025 Net profit of €30.7m in 2024, recording a strong growth of +66.7% over 2023 Robust balance sheet with a net leverage of 1.2x at year-end 2024, enabling the execution of our growth strategy Proposed payment of a €0.10 cash dividend per share for the 2024 fiscal year, for the first...

BALTIMORE, Feb. 28, 2025 (GLOBE NEWSWIRE) — MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or the “Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today reported financial results for fourth quarter 2024.(1) Fourth Quarter 2024 Highlights(1)(2)Paid Subscribers were 506 thousand as of December 31, 2024 compared with 737 thousand as of December 31, 2023 Total Net Revenue was $97.5 million in 4Q 2024 compared with $112.2 million in 4Q 2023 Total Billings was $55.4 million in 4Q 2024 compared with $93.6 million in 4Q 2023 Net Income was $26.4 million in 4Q 2024 compared with $1.9 million in 4Q 2023 Cash from Operating Activities of $6.0 million in 4Q 2024 compared with $17.5 million in 4Q 2023 Cash and Cash...

MONTRÉAL, Feb. 28, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its unaudited Quarterly Consolidated Financial Statements and MD&A for its first quarter ended on December 31st, 2024.     Highlights     (in thousands of Canadian dollars) Dec. 30, 2024(3 months) Dec. 30, 2023(3 months)Revenues 32,132   36,973  Gross margin (1) 5,137   7,657  Gross margin as a % of revenues 16.0 % 20.1 %Adjusted EBITDA (1) 705   2,622  Net Loss (2,261 ) (231 )(1)  See the Corporation’s MD&A for details on these non-GAAP measures.   SummaryAdjusted EBITDA for the quarter was $0.7M ($2.6M for the same period in 2023), mainly driven by a decline in the Quebec market. Net Loss for the quarter was $2.3M...

Presented positive interim data through 52 weeks and beyond for 4D-150 in wet AMD from PRISM Phase 1/2 clinical trial highlighting robust and durable clinical activity across diverse patient populations and continued favorable tolerability      Announced positive interim 32-week data for 4D-150 in DME from Part 1 of SPECTRA clinical trial and alignment with FDA for a single Phase 3 trial being acceptable for the basis of BLA submission for 4D-150 in DME when combined with data generated from 4FRONT Phase 3 trials in wet AMD 4FRONT Phase 3 program in wet AMD on track with initiation of 4FRONT-1 expected in March 2025 and 4FRONT-2 in Q3 2025, with topline data from both studies expected in 2H 2027 Strategically focused pipeline to optimize resource allocation and extend cash runway to advance product candidates with strongest clinical proof...

Wa’el HashadWa’el Hashad, Chief Executive Officer, Longeveron Inc.Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025 Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successful FDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer’s disease WHO International Nonproprietary Names (INN) Expert Committee approved “laromestrocel” for the non-proprietary name of Lomecel-B™ Total Revenue for 2024 increased 237% year-over-year...

Net income on an adjusted basis increased 9% in the fourth quarter and 23% for the year SHELTON, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) today announced that net sales for the quarter ended December 31, 2024 were $45.9 million compared to $41.9 million in the fourth quarter of 2023, an increase of 10%. Net sales for the year ended December 31, 2024 were $194.5 million compared to $191.5 million in 2023, an increase of 2%. Excluding the impact of the sale of the Camillus and Cuda hunting and fishing product lines on November 1, 2023, net sales for 2024 increased 6% compared to 2023. Net income for the quarter ended December 31, 2024 was $1.70 million, or $0.41 per diluted share, compared to $1.56 million, or $0.40 per diluted share (as adjusted) for the same period in 2023 an increase...